Published in Gene Therapy Weekly, February 24th, 1997
Daniel Kisner, M.D., Isis, presented data on the drug at the International Business Communications Meeting on Antisense Therapeutics, held in San Diego, California. Fomivirsen also is effective in AIDS patients who have failed newer CMV retinitis agents such as Vitrasert and Vistide, as well as standard agents.
Isis expects to complete Phase III of fomivirsen trials later in 1997.
Kisner also discussed the positive efficacy results from the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (1997-02-24)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.